Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | ASTX030 |
| Synonyms | |
| Therapy Description |
ASTX030 is a combination of azacitidine and cedazuridine, which may lead to inhibition of cell proliferation of tumor cells (Blood (2019) 134 (Supplement_1): 1376). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| ASTX030 | ASTX 030|ASTX-030|AZA/CDZ Combination|Cedazuridine + Azacitidine | ASTX030 is a combination of azacitidine and cedazuridine, which may lead to inhibition of cell proliferation of tumor cells (Blood (2019) 134 (Supplement_1): 1376). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04256317 | Phase II | ASTX030 ASTX030 + Azacitidine + Venetoclax ASTX030 + Azacitidine ASTX030 + Azacitidine + Cedazuridine | A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study) (AZTOUND) | Recruiting | USA | POL | ITA | HUN | GBR | FRA | ESP | DEU | CZE | CAN | 0 |